{
    "clinical_study": {
        "@rank": "38668", 
        "arm_group": {
            "arm_group_label": "Patients with diabetes mellitus requiring insulin therapy"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in Asia. The aim of the study is to evaluate long term safety and\n      efficacy of Tresiba\u00ae (insulin degludec) in patients with diabetes mellitus in routine\n      clinical practice in India."
        }, 
        "brief_title": "A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba\u00ae (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any study-related activities (Study related\n             activities are any procedure related to recording of data according to the protocol).\n             The historical data including the data before informed consent obtained (e.g.\n             glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), severe hypoglycaemia\n             before the start of Tresiba\u00ae therapy) can be used for baseline data\n\n          -  Patients with insulin requiring diabetes mellitus and who is scheduled to start\n             treatment with Tresiba\u00ae based on the clinical judgment of their treating physician\n\n        Exclusion Criteria:\n\n          -  Known or suspected allergy to Tresiba\u00ae, the active substance or any of the excipients\n\n          -  Previous participation in this study\n\n          -  Mental incapacity, unwillingness or language barriers precluding adequate\n             understanding or cooperation\n\n          -  Patients who are or have previously been on Tresiba\u00ae therapy\n\n          -  Patients who are participating in other studies or clinical trials\n\n          -  Patients who are pregnant, breast feeding or have the intention of becoming pregnant\n             within the following 12 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with diabetes mellitus requiring insulin therapy who qualify for starting\n        treatment with Tresiba\u00ae based on the clinical judgment by their treating physician during\n        enrolment period."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117622", 
            "org_study_id": "NN1250-4129", 
            "secondary_id": "U1111-1145-9828"
        }, 
        "intervention": {
            "arm_group_label": "Patients with diabetes mellitus requiring insulin therapy", 
            "description": "Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba\u00ae is decided in advance of this study.", 
            "intervention_name": "insulin degludec", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba\u00ae (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events (AEs) by preferred term", 
            "safety_issue": "No", 
            "time_frame": "During 1 year of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of serious adverse events (SAEs) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 1 year of treatment"
            }, 
            {
                "measure": "Incidence of serious adverse drug reactions (SADRs) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 1 year of treatment"
            }, 
            {
                "measure": "Incidence of adverse drug reactions (ADRs) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 1 year of treatment"
            }, 
            {
                "measure": "Incidence of severe hypoglycaemia", 
                "safety_issue": "No", 
                "time_frame": "During 1 year of treatment"
            }, 
            {
                "measure": "Change from baseline in glycosylated haemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1, week 0), end of study (Visit 4, week 52)"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1, week 0), end of study (Visit 4, week 52)"
            }, 
            {
                "measure": "Incidence of confirmed hypoglycaemia", 
                "safety_issue": "No", 
                "time_frame": "During 1 year of treatment"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}